However, the concept of treating acute respiratory failure (ARDS) in COVID-19 patients with human recombinant ACE2 (rhACE2) seems to be theoretically justified due to viral binding and angiotensin (1-7) synthesis. The gene discussed is AGT; the disease is acute respiratory failure.